AstraZeneca's Prostate Cancer Supplemental Drug Gets U.S. Approval

Date : 01/20/2020 @ 7:46AM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 7446.0  -244.0 (-3.17%) @ 4:35PM

AstraZeneca's Prostate Cancer Supplemental Drug Gets U.S. Approval

Astrazeneca (LSE:AZN)
Historical Stock Chart

2 Months : From Dec 2019 to Feb 2020

Click Here for more Astrazeneca Charts.
   By Sabela Ojea 

AstraZeneca PLC (AZN.LN) said Monday that its supplemental new drug application for Lynparza has been accepted and granted priority review in the U.S. by the Food and Drug Administration for patients with metastatic castration-resistant prostate cancer.

The pharmaceutical company said that the Prescription Drug User Fee Act date is set for the second quarter of 2020.

The London-listed company said that Lynparza is also aimed at patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutations, which have progressed following prior treatment with a new hormonal agent.

Results of the PROfound trial showed Lynparza significantly reduced the risk of disease progression or death by 66%, it added.

Prostate cancer is the second-most common cancer in men, with an estimated 1.3 million new cases diagnosed world-wide in 2018 and it is associated with a significant mortality rate, AstraZeneca noted.


Write to Sabela Ojea at; @sabelaojeaguix


(END) Dow Jones Newswires

January 20, 2020 02:31 ET (07:31 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.